11-25-2013, 05:50 PM
The prevailing drug Nexavar is once again approved by FDA on 22nd November 2013 to treat yet another type of cancer, the metastatic Thyroid cancer (highly differentiated). This is the third approval bagged by the drug Nexavar a product of Bayer and Onyx Pharma in addition to the earlier approval of the drug in 2005 to treat highly developed renal cell carcinoma (Kidney cancer) and approval in 2007 to treat hepatocellular carcinoma (liver cancer). Nexavar is also designated as the orphan product by FDA.
Thyroid cancer is a condition of malignancy in thyroid gland. It is classified into different types like papillary, follicular, medullary, poorly differentiated and anaplastic thyroid cancer among which the papillary and follicular thyroid cancer are the two types categorized under differentiated thyroid cancer. Papillary thyroid cancer constitutes about 75% to 85% of thyroid cancer cases and follicular thyroid cancer amounts up to 10% to 20% of thyroid cancer cases. A study by American cancer society states that in the current year about 1040 females and 810 male will succumb to thyroid cancer. Surgical removal of thyroid gland, radioactive iodine therapy and chemotherapy are the considered options carried out to better the lives of the thyroid cancer patients and Nexavar is an assurance to thyroid cancer patients who does not respond to any of these conventional treatment methods.
The effectiveness of the drug Nexavar is acknowledged through the findings from the clinical study. Treatment with Nexavar is found to prolong the survival period (with no cancer progression) of the affected persons to about 41 percent compared to the patient category treated with placebo. The study was conducted on patients with metastatic (differentiated) thyroid cancer and patients with the history of recurrence of thyroid cancer at the local site who did not respond to the existing treatment methods.
Nexavar also called as Sorafenib gains control over the growth of the cancer cells by functioning as a protein inhibitor. Some of the side effects should the patient using Nexavar therapy be aware are restricted blood flow, bleeding, skin disease, hair loss, fluctuating Thyroid hormone level, liver inflammation, fatigue and diarrhea. Patients are advised to be transparent to the doctors about all the other medications taken by them before starting Nexavar therapy and also should discuss about any allergies they are prone to. Nexavar taken by pregnant women poses devastating effect on the fetus and it is advisable for female patients not to try to conceive while taking Nexavar.
Thus Nexavar occupies a prominent place in the list of treatment methods available to treat kidney, Liver and Thyroid cancer.
Reference
http://www.fda.gov/NewsEvents/Newsroom/P...376443.htm
http://in.reuters.com/article/2013/11/22...4F20131122
http://www.nexavar-us.com/scripts/pages/.../index.php
http://en.wikipedia.org/wiki/Thyroid_cancer
http://www.uptodate.com/contents/differe...management
http://www.rxlist.com/nexavar-drug.htm
Thyroid cancer is a condition of malignancy in thyroid gland. It is classified into different types like papillary, follicular, medullary, poorly differentiated and anaplastic thyroid cancer among which the papillary and follicular thyroid cancer are the two types categorized under differentiated thyroid cancer. Papillary thyroid cancer constitutes about 75% to 85% of thyroid cancer cases and follicular thyroid cancer amounts up to 10% to 20% of thyroid cancer cases. A study by American cancer society states that in the current year about 1040 females and 810 male will succumb to thyroid cancer. Surgical removal of thyroid gland, radioactive iodine therapy and chemotherapy are the considered options carried out to better the lives of the thyroid cancer patients and Nexavar is an assurance to thyroid cancer patients who does not respond to any of these conventional treatment methods.
The effectiveness of the drug Nexavar is acknowledged through the findings from the clinical study. Treatment with Nexavar is found to prolong the survival period (with no cancer progression) of the affected persons to about 41 percent compared to the patient category treated with placebo. The study was conducted on patients with metastatic (differentiated) thyroid cancer and patients with the history of recurrence of thyroid cancer at the local site who did not respond to the existing treatment methods.
Nexavar also called as Sorafenib gains control over the growth of the cancer cells by functioning as a protein inhibitor. Some of the side effects should the patient using Nexavar therapy be aware are restricted blood flow, bleeding, skin disease, hair loss, fluctuating Thyroid hormone level, liver inflammation, fatigue and diarrhea. Patients are advised to be transparent to the doctors about all the other medications taken by them before starting Nexavar therapy and also should discuss about any allergies they are prone to. Nexavar taken by pregnant women poses devastating effect on the fetus and it is advisable for female patients not to try to conceive while taking Nexavar.
Thus Nexavar occupies a prominent place in the list of treatment methods available to treat kidney, Liver and Thyroid cancer.
Reference
http://www.fda.gov/NewsEvents/Newsroom/P...376443.htm
http://in.reuters.com/article/2013/11/22...4F20131122
http://www.nexavar-us.com/scripts/pages/.../index.php
http://en.wikipedia.org/wiki/Thyroid_cancer
http://www.uptodate.com/contents/differe...management
http://www.rxlist.com/nexavar-drug.htm
![[+]](https://www.biotechnologyforums.com/images/netpen-pro/collapse_collapsed.png)